DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Lobe Sciences (CSE:LOBE,OTCQB: LOBEF) is taking a different approach to psychedelic treatment by using low-dose, sub-psychedelic stimulation targeting the right receptor to achieve better outcomes for patients.
“Our whole philosophy is that we don’t believe you have to go on a psychedelic trip to get the benefit of the therapeutic interventions,” Lobe Science CEO Philip J. Young. “The business model where patients are confined to a clinic for 8 to 12 hours and undergo a psychedelic trip, to me is not the best way to create a global pharmaceutical market.”
Lobe Sciences is a life sciences company focused on the research and development of psychedelic medicines to treat neurological disorders and brain traumas. The company has made some progress developing psilocybin-based treatment for anxiety disorders, and is also targeting treatment for pediatric orphan disease, an often life-threatening or serious rare condition among children, Young said.
“The kids really need some therapeutic intervention and some help. So, we’re in a position now where we control our drug supply. We have clinical development plans, and we’ll actually be dosing our first patient in clinical trials this month,” Young said.
Young said his company is set to submit an investigational new drug application with the US Food and Drug Administration for an orphan drug for pediatric indication. It will also be commencing its first human study using its proprietary compounds.
Lobe Sciences recently expanded its patent portfolio by filing international patents for methods, and devices that treat mild traumatic brain injury and post-traumatic stress disorder.
Investing News Network (INN)
Find out more about investing by INN @
Want a FREE investor kit? Download here↓
Follow us Facebook:
Follow us on Twitter:
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.